Toxicity Profile of Lisdexamfetamine Dimesylate in Three Independent Rat Toxicology Studies
Authors:
- 10 August 2007
- journal article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 101 (4) , 231-240
Abstract
Abstract: Lisdexamfetamine dimesylate (LDX) is a d‐amphetamine prodrug developed for the treatment of attention‐deficit/hyperactivity disorder. The toxicity profile of orally administered LDX has been evaluated in rats. In an acute study, LDX doses of 60 mg/kg and higher caused increased motor activity. At 1000 mg/kg, one rat died and another was euthanized. In a 7‐day repeat‐dose study, all rats dosed with LDX (14 per dose group for each sex) showed increased activity; 10 male rats and 11 female rats at 300 mg/kg/day and 3 female rats at 100 mg/kg/day were euthanized because of self‐mutilation and 1 male rat at 300 mg/kg/day was found dead. In a 28‐day study, only rats at 80 mg/kg showed signs of self‐mutilation and thin body condition. In both the 7‐ and 28‐day studies, LDX caused significant changes in some blood chemistry parameters (e.g. blood urea nitrogen, alanine aminotransferase, aspartate aminotransferase) and organ weights (e.g. particularly heart, liver, brain, and spleen). Overall, no apparent treatment‐related histopathologic changes were observed. Toxicokinetic assessments indicated that as the dose of LDX was increased, rats were exposed to increasing levels of LDX and d‐amphetamine. The extent of exposure to LDX and d‐amphetamine increased after repeated‐dose in the 28‐day study. The findings of the repeat‐dose studies indicate that the toxicity profile in rats administered LDX orally is comparable to that for d‐amphetamine; however, the apparent lethal dose of LDX in rats is more than five times higher than the LD50 of orally administered d‐amphetamine, supporting a putative protective effect of conjugating amphetamine with lysine.Keywords
This publication has 10 references indexed in Scilit:
- The Texas Children's Medication Algorithm Project: Revision of the Algorithm for Pharmacotherapy of Attention-Deficit/Hyperactivity DisorderJournal of the American Academy of Child & Adolescent Psychiatry, 2006
- Attention-deficit hyperactivity disorderThe Lancet, 2005
- Update on attention-deficit/hyperactivity disorderCurrent Opinion in Pediatrics, 2004
- Advances in the Pharmacotherapy of Attention‐Deficit‐Hyperactivity Disorder: Focus on Methylphenidate FormulationsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003
- Physician Perceptions of the Use of Medications for Attention Deficit Hyperactivity DisorderJournal of Managed Care Pharmacy, 2003
- Does Stimulant Therapy of Attention-Deficit/Hyperactivity Disorder Beget Later Substance Abuse? A Meta-analytic Review of the LiteraturePediatrics, 2003
- A 90-day oral gavage toxicity study of d-methylphenidate and d,l-methylphenidate in Sprague–Dawley ratsToxicology, 2002
- Pharmacotherapy of Attention Deficit Hyperactivity DisorderChild and Adolescent Psychiatric Clinics of North America, 2000
- Effect of d -amphetamine repeated administration on rat antioxidant defencesArchives of Toxicology, 1999
- Practice Parameters for the Assessment and Treatment of Children, Adolescents, and Adults With Attention-Deficit/Hyperactivity DisorderJournal of the American Academy of Child & Adolescent Psychiatry, 1997